ZYDUSLIFE
Zydus Lifesciences Limited
Each stock's 10,000-path forecast, rendered as light.
Zydus Lifesciences Limited (ZYDUSLIFE) Stock Analysis & Case Study
Is ZYDUSLIFE a good buy? The data-driven verdict.
Zydus Lifesciences Limited (ZYDUSLIFE) trades at ₹1,114,on the numbers it screens attractive, a Downstox Snapshot Score of 79/100.
On the numbers, Zydus Lifesciences Limited (ZYDUSLIFE) screens attractive, a Downstox Snapshot Score of 79/100, weighing fairly valued at 20.5× earnings, ROE of 21.2%, a 65% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
ZYDUSLIFE fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How ZYDUSLIFE ranks against the 2,373 companies in our screener
- ZYDUSLIFE's market cap of 1.11L Cr ranks in the top 4% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ZYDUSLIFE's book value of ₹269 ranks in the 79th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ZYDUSLIFE's promoter holding of 75.0% ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ZYDUSLIFE's 3-year profit (PAT) growth of 32.0% ranks in the 71st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ZYDUSLIFE's 3-year revenue growth of 16.0% ranks in the 65th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ZYDUSLIFE's debt-to-equity ratio of 0.46x is lower than 38% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is ZYDUSLIFE overvalued? ZYDUSLIFE P/E vs its Pharma
ZYDUSLIFE's P/E of 20.5× sits below the Pharma peer median of 30.4×, so on earnings it screens cheaper than peers, while its 0.09% dividend yield is below the peer median of 0.68%.
ZYDUSLIFE share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of ZYDUSLIFE history (11%/yr drift, 24%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| ZYDUSLIFE 2027 | ₹902 | ₹1,220 | ₹1,652 | +10% |
| ZYDUSLIFE 2028 | ₹873 | ₹1,337 | ₹2,045 | +20% |
| ZYDUSLIFE 2029 | ₹863 | ₹1,464 | ₹2,482 | +31% |
| ZYDUSLIFE 2030 | ₹875 | ₹1,603 | ₹2,939 | +44% |
| ZYDUSLIFE 2031 | ₹894 | ₹1,756 | ₹3,449 | +58% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability ZYDUSLIFE goes up, or doubles?
The bull case for ZYDUSLIFE
- ZYDUSLIFE's P/E of 20.5x is lower than 61% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ZYDUSLIFE's return on equity of 21.2% ranks in the 86th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- ZYDUSLIFE's return on capital employed of 21.1% ranks in the 82nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A 10,000-path probability model puts a 65% chance the price is higher in a year, with a median target of ₹1,220 (+10%).
- Relatively low volatility (24%/yr), a steadier ride than the typical mid/small-cap.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,482.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹863.
ZYDUSLIFE volatility & expected range, how bumpy is the ride?
Over the last 9.8 years ZYDUSLIFE compounded at 11%/year with annualized volatility of 24%. That volatility implies a 1-year 80% range of ₹902-₹1,652, the honest backbone behind any single price target.
ZYDUSLIFE price forecast, the full 60-month probability fan
ZYDUSLIFE price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds ZYDUSLIFE hits common targets within the simulated horizon?
Full multi-horizon detail on the ZYDUSLIFE price target & forecast page.
ZYDUSLIFE Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. ZYDUSLIFE scores 6/8, mixed financial health.
ZYDUSLIFE MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy ZYDUSLIFE with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 23.16% | 4.3× |
| Zerodha | 22.70% | 4.4× |
| Groww | 22.75% | 4.4× |
| Dhan | 22.00% | 4.5× |
| Kotak NeoCHEAPEST | 20.00% | 5.0× |
| Paytm MoneyCHEAPEST | 20.00% | 5.0× |
| Pocketful | 26.86% | 3.7× |
| Fyers | 27.03% | 3.7× |
| Anand Rathi | 26.64% | 3.8× |
| Bajaj Broking | 23.00% | 4.3× |
| Share India | 26.70% | 3.7× |
Compare every broker on the ZYDUSLIFE MTF page.
ZYDUSLIFE vs peers,Pharma comparison
| Stock | P/E | Div yield | Market cap |
|---|---|---|---|
| ZYDUSLIFE (this stock) | 20.5× | 0.09% | ₹1.11L Cr |
| SUNPHARMA | 36.9× | 0.82% | ₹4.67L Cr |
| DIVISLAB | 73.7× | 0.36% | ₹2.20L Cr |
| DRREDDY | 30.4× | 0.68% | ₹97,824 Cr |
| CIPLA | 33.0× | 0.89% | ₹1.18L Cr |
| LUPIN | 18.2× | 0.76% | ₹1.08L Cr |
| AUROPHARMA | 25.5× | 0.24% | ₹96,297 Cr |
Fundamentals from Screener.in, as of 9 Aug 2026
About Zydus Lifesciences Limited: sector, index & market-cap context
Zydus Lifesciences Limited (ZYDUSLIFE) is a large-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 500 index, with a market capitalisation of ₹1.11L Cr. See more stocks on our screener.
How the ZYDUSLIFE Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Zydus Lifesciences Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ZYDUSLIFE analysis, FAQs
Is Zydus Lifesciences Limited (ZYDUSLIFE) a good buy?
On the numbers, Zydus Lifesciences Limited (ZYDUSLIFE) screens attractive, a Downstox Snapshot Score of 79/100, weighing fairly valued at 20.5× earnings, ROE of 21.2%, a 65% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is ZYDUSLIFE overvalued or undervalued?
ZYDUSLIFE trades at 20.5× earnings versus a peer median of 30.4×, so it screens cheaper than its Pharma peers.
What is the ZYDUSLIFE share price target for 2031?
ZYDUSLIFE's probability-weighted 2031 median target is ₹1,756, with an 80% range of ₹894-₹3,449 (10,000-path Monte-Carlo).
What is the probability ZYDUSLIFE doubles in 5 years?
The modelled probability of ZYDUSLIFE reaching ₹2,228 (2×) within 5 years is 33%.
What is the bull case for ZYDUSLIFE?
ZYDUSLIFE's P/E of 20.5x is lower than 61% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. ZYDUSLIFE's return on equity of 21.2% ranks in the 86th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. ZYDUSLIFE's return on capital employed of 21.1% ranks in the 82nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in ZYDUSLIFE?
No model or past record guarantees future returns, treat this as one input, not a decision.